Profit

BSE Code: | NSE Code: | ISIN: | Sector:

NSE
354.95
Change Change %
-4.35 -1.21%

Updated:16 Nov, 2018, 14:24 PM IST

BSE
352.70
Change Change %
-7.05 -1.96%

Updated:16 Nov, 2018, 14:52 PM IST

Research Report Detail

Brokerage
Analyst
Report Date Call Price@Call Target Price
Stop Loss
Current Status Time Horizon
Nomura
N/A
24-08-2017 Hold 497.90 464.00
N/A
Target Hit Long (1Y)
24-08-2018

Nomura maintains neutral on Cadila Healthcare

Cadila Healthcare's (CDH) approval momentum in the US remains strong. In FY18, the company has received 30 final approvals so far, of which 12 are from the recently cleared Moraiya facility. With more than 50 approvals from Moraiya still pending and high filing intensity in the past, we expect CDH to gain around 150 ANDA approvals over FY18-20F, vs. 101 till FY17. Importantly, the company has received the approval for gLialda and gAsacol HD, which we believe are the two largest opportunities in the pipeline.

Top